Skip to main content
  • Site Staff Website Access Request Form
  • Connect With Us
  • Login

Search form

Home
  • About BMT CTN
    • What We Do
    • Why We Do What We Do
    • Who’s Involved
    • Clinical Centers
    • Enrollment in BMT CTN Studies
    • Our Annual Progress Report
    • Publications
    • State of the Science Symposia
    • Our History
    • Study Summaries for Patients
  • BMT CTN Studies
  • Investigator & Research Staff Resources
    • Overview
    • Administrative Manual of Procedures (MOP)/Policy Guidelines
    • Center Membership & Study Participation
    • Resources for Research Coordinators
    • Correlative Study Proposals
    • Funding Opportunities
    • Technical and Administrative Committees
    • Author Resources
  • Partner With Us

Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial.

TitleAutologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial.
Publication TypeJournal Article
Year of Publication2016
AuthorsAlvarnas, JC, Le Rademacher, J, Wang, Y, Little, RF, Akpek, G, Ayala, E, Devine, S, Baiocchi, R, Lozanski, G, Kaplan, L, Noy, A, Popat, U, Hsu, J, Morris, LE, Thompson, J, Horowitz, MM, Mendizabal, A, Levine, A, Krishnan, A, Forman, SJ, Navarro, WH, Ambinder, R
JournalBlood
Volume128
Issue8
Pagination1050-8
Date Published2016 08 25
ISSN1528-0020
KeywordsAdult, Bone Marrow Transplantation, CD4 Lymphocyte Count, Databases as Topic, Demography, Disease-Free Survival, Female, Hematopoietic Stem Cell Transplantation, Humans, Lymphoma, AIDS-Related, Male, Middle Aged, Transplantation, Autologous, Treatment Outcome, Viral Load, Young Adult
Abstract

Autologous hematopoietic cell transplant (AHCT) for HIV-infected patients is largely limited to centers with HIV-specific expertise. The Blood and Marrow Transplant Clinical Trials Network 0803/AIDS Malignancy Consortium 071 trial is a multicenter phase 2 study of AHCT for patients with HIV-related lymphoma (HRL). Eligible patients had chemotherapy-sensitive relapsed/persistent HRL, were >15 years of age, and had treatable HIV infection. Patients were prepared using carmustine, etoposide, cytarabine, and melphalan and received consistent management of peritransplant antiretroviral treatment. The primary endpoint was 1-year overall survival. Forty-three patients were enrolled; 40 underwent AHCT. Pretransplant HIV viral load was undetectable (

DOI10.1182/blood-2015-08-664706
Alternate JournalBlood
PubMed ID27297790
PubMed Central IDPMC5000843
Grant ListU10 HL069294 / HL / NHLBI NIH HHS / United States
K12 HD001399 / HD / NICHD NIH HHS / United States
U10 HL069278 / HL / NHLBI NIH HHS / United States
U24 CA076518 / CA / NCI NIH HHS / United States
UG1 HL069278 / HL / NHLBI NIH HHS / United States
U10 HL069310 / HL / NHLBI NIH HHS / United States
U10 HL109137 / HL / NHLBI NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States
UM1 CA121947 / CA / NCI NIH HHS / United States
U01 CA121947 / CA / NCI NIH HHS / United States
  • Google Scholar
  • PubMed
  • DOI

Blood & Marrow Transplant Clinical Trials Network (BMT CTN)

Blood and Marrow Transplant Clinical Trials Network Twitter

Copyright © 2023, The Emmes Company LLC